全球6823家药企,中国生物制药管线规模排行第15位

动脉网
09 May

中国生物制药在全球药企管线规模排名中位列第15,新药研发成果显著,2024年营收超288亿元人民币,创新药收入达到120.6亿元。公司将在2025年ASCO大会上披露40多项临床研究数据,展示其创新实力,并通过持续的创新药研发,争夺全球市场份额。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10